The synergistic effects that were evident in most of the combination regimens indicated that the Btk inhibitor ibrutinib can sensitize cancer cells to platinum, whereas the additive effects indicated that both drugs independently eliminated cancer cells. The gene discussed is BTK; the disease is cancer.